LENZ Therapeutics (LENZ) Q2 2024 earnings summary

Executive summary

• Achieved public market debut via reverse merger, submitted NDA to FDA for LNZ100 for presbyopia, and completed $30M PIPE financing in July 2024.

• LNZ100 demonstrated rapid, durable, and clinically meaningful improvement in near vision in Phase 3 CLARITY trials, with a strong safety and tolerability profile.

• Commercial launch preparations are underway, targeting a potential US launch in the second half of 2025, pending FDA approval.

• Presbyopia market opportunity exceeds $3B in the US, with 128M affected and limited pharmacologic competition.

• Financial position strengthened by PIPE financings and merger, with pro forma cash and equivalents at $226.2M as of June 30, 2024.

Financial highlights

• Ended Q2 2024 with $196.1M in cash, cash equivalents, and marketable securities; pro forma $226.2M including July PIPE financing.

• Q2 2024 operating expenses were $14.4M; R&D expenses dropped to $6.9M, and SG&A rose to $7.4M, reflecting commercial buildout.

• Net loss for Q2 2024 was $10.3M ($0.40 per share), down from $14.7M ($7.53 per share) in Q2 2023.

• Other income, net, rose to $4.1M in Q2 2024, primarily due to higher interest income and fair value adjustments.

• No revenue expected from product sales until regulatory approval and launch of LNZ100.

Outlook and guidance

• Anticipates FDA approval for LNZ100 by mid-2025, with US launch possible in the second half of 2025.

• Cash runway expected to fund operations through post-launch positive operating cash flow.

• SG&A expected to ramp further in 2025 as commercialization nears; R&D expenses projected to continue declining.